TG Therapeutics, Inc. - Common Stock (TGTX)
35.62
+1.20 (3.49%)
Tg Therapeutics is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of various hematologic malignancies and autoimmune diseases
With a strong emphasis on targeted therapies, the company aims to improve patient outcomes through its proprietary drug candidates, which are designed to engage the immune system in a more effective manner. Tg Therapeutics is committed to advancing its research and development efforts to address unmet medical needs in these challenging therapeutic areas, leveraging the latest scientific advancements to enhance patient care.

Annual revenue from its MS drug, Briumvi, more than tripled, with U.S. net product revenue reaching $103.6 million in the fourth quarter and $310 million for the full year.
Via Stocktwits · March 3, 2025

Despite earlier indicating a strong start to March, stocks are lower this afternoon amid trade war concerns.
Via Talk Markets · March 3, 2025

The company has gained notoriety for its multiple sclerosis treatment.
Via Investor's Business Daily · March 3, 2025

Via Benzinga · January 15, 2025

Via Benzinga · November 25, 2024

Via Benzinga · February 26, 2025

TG Therapeutics Inc (NASDAQTGTX) shares are trading higher. The company on Tuesday provided guidance for the fourth quarter and full-year 2024.
Via Benzinga · January 14, 2025

NASDAQ:TGTX is showing decent growth, but is still valued reasonably.
Via Chartmill · November 21, 2024

Via Benzinga · November 21, 2024

Via Benzinga · November 12, 2024

Via Benzinga · October 29, 2024

Why TG THERAPEUTICS INC (NASDAQTGTX) qualifies as a high growth stock.
Via Chartmill · October 21, 2024

A Fed rate cut and a slew of big earnings reports filled out a busy week.
Via Investor's Business Daily · November 8, 2024

The company raised its sales outlook for the year, though, following stronger-than-expected revenue from its only product.
Via Investor's Business Daily · November 4, 2024

Via Benzinga · November 4, 2024

Is TG THERAPEUTICS INC (NASDAQTGTX) suited for high growth investing?
Via Chartmill · October 15, 2024

Via Benzinga · November 4, 2024

Via Benzinga · November 4, 2024

Two of the 5 top stocks to watch this week tap the artificial intelligence market.
Via Investor's Business Daily · November 2, 2024

Amid the election, and a Fed rate vote, earnings season roars ahead.
Via Investor's Business Daily · November 1, 2024

TG THERAPEUTICS INC (NASDAQTGTX) stands out as a growth opportunity that won't break the bank.
Via Chartmill · October 30, 2024

TG THERAPEUTICS INC (NASDAQTGTX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via Chartmill · October 15, 2024

NASDAQ:TGTX is showing decent growth, but is still valued reasonably.
Via Chartmill · October 9, 2024